ArticleCancer chemotherapy and pharmacology2024

Correction to: An IQ consortium analysis of starting dose selection for oncology small molecule first‑in‑patient trials suggests an alternative NOAEL‑based method can be safe while reducing time to the recommended phase 2 dose.

Bart A Jessen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.